ClinicalTrials.gg
Not yet recruitingNCT07528196Updated Jun 5, 2026

Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome

A Phase 3 interventional study of Xuanbai Shengmai Decoction in Acute Respiratory Distress Syndrome (ARDS), sponsored by Southeast University, China. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Southeast University, China · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Respiratory Distress Syndrome by Southeast University, China — 10 open to participants now, 10 under way, 2 of them phase 3. Respiratory Distress Syndrome · Southeast University, China.

Planned enrollment
3rd of 11
308 · median 93
Started
2026
with 4 others
Phase 3
2 of 24
2 open now
Registered
21st of 24
by date

Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 3, and was the 21st registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

10 of the 24 studies in Respiratory Distress Syndrome by Southeast University, China are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Respiratory Distress Syndrome by Southeast University, China, or all of them as a file.
02

Study summary

Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and therapeutic efficacy in ARDS has become a hotspot.As characterized by syndrome differentiation, traditional Chinese medicine (TCM) treatment emphasizes interindividual heterogeneity and personalized management, which is expected to serve as a breakthrough in multi-target immune regulation for ARDS. The primary objective of the study is to investigate the effect of Xuanbai Shengmai Decoction on the prognosis of patients with ARDS in a prospective randomized controlled trial. The secondary objective is to evaluate the safety of Xuanbai Shengmai Decoction in the treatment of patients with ARDS.

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)

Keywords

  • Acute Respiratory Distress Syndrome (ARDS)
  • Traditional Chinese Medicine
  • Xuanbai Shengmai Decoction
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Met the diagnostic criteria for ARDS according to the 2023 updated global definition.
  2. Within 48 hours of meeting the diagnostic criteria.
  3. Aged ≥ 18 years and ≤ 85 years.

Exclusion criteria

Exclusion Criteria:

  1. Did not meet the diagnostic criteria.
  2. Pregnant or lactating women.
  3. Patients with gastrointestinal dysfunction (including gastrointestinal bleeding, severe intra-abdominal hypertension, severe intestinal obstruction, etc.), resulting in the inability to administer medication via nasogastric/nasoenteric tube or orally within 48 hours after enrollment.
  4. SOFA score > 13.
  5. to the study drugs.
  6. Withdrawal of treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
308 participants (estimated)

Study arms

  • No intervention
    Control Group

    Patients in the control group will receive standard comprehensive Western medical treatment.

  • Experimental
    Treatment Group

    Patients in the treatment group will receive Xuanbai Shengmai Decoction via oral administration or nasogastric feeding on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day divided into two administrations, for a total treatment duration of 7 days.

    Drug: Xuanbai Shengmai Decoction

Interventions

  • DrugXuanbai Shengmai Decoction

    Patients in the treatment group will receive Xuanbai Shengmai Decoction orally or via nasogastric gavage on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day in two divided administrations, for a total of 7 days.

06

What researchers measure

Primary outcomes

  1. 28-day mortality

    Mortality was calculated on day 28 of treatment.

    Time frame: On day 28 of treatment

Secondary outcomes

  1. Clinical scoring indicator: LIS

    Clinical scores were assessed before treatment, on day 3 of treatment, and on day 7 of treatment.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  2. Inflammatory indicator: Interleukin-6 (IL-6,pg/mL)

    Serum IL-6 levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  3. Pulmonary vascular permeability indicator: Serum angiopoietin-2 (Ang-2,pg/mL)

    The concentration of angiopoietin-2 in peripheral blood (pg/mL) will be measured at baseline (pre-treatment), Day 3, and Day 7 of treatment, as a biomarker of pulmonary vascular permeability.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  4. Lung injury indicator:Oxygenation index (PaO₂/FiO₂ ratio)

    Arterial blood gas samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to determine the ratio of arterial partial pressure of oxygen (PaO₂) to the fraction of inspired oxygen (FiO₂), which will be used to assess the patient's oxygenation status.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  5. Ventilator parameter: Tidal volume (VT, mL)

    The ventilator-set tidal volume (in mL) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  6. Duration of mechanical ventilation

    Duration of mechanical ventilation within 28 days

    Time frame: within 28 days

  7. Length of ICU stay

    Time of staying in ICU within 28 days

    Time frame: within 28 days

  8. Multiplex detection:Pathogen Load by Multiplex PCR

    Throat swabs, fecal samples (10g), and peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Multiplex PCR will be performed to detect the nucleic acid load of target pathogens, with the unit of copies/mL, to evaluate changes in infection burden.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  9. Clinical scoring indicator:Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score

    Assessed using the full APACHE Ⅱ scale at baseline (pre-treatment), Day 3, and Day 7 of treatment. The scale consists of three components: acute physiology score, age score, and chronic health evaluation score, with a total score ranging from 0 to 71. Higher scores indicate greater severity of illness and higher risk of mortality.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  10. Clinical scoring indicators: Sequential Organ Failure Assessment (SOFA) score

    Assessed using the full Sequential Organ Failure Assessment scale at baseline (pre-treatment), day 3, and day 7 of treatment. The score evaluates the function of six organ systems: respiratory, coagulation, hepatic, cardiovascular, neurological, and renal, with a total range of 0-24. Higher scores indicate more severe organ dysfunction and a worse prognosis.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  11. Lung injury indicator:Static lung compliance( mL/cmH₂O)

    Static lung compliance ( mL/cmH₂O) will be calculated via the ventilator monitoring platform under constant tidal volume and plateau pressure conditions at baseline (pre-treatment), Day 3, and Day 7 of treatment, to assess respiratory mechanics function.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  12. Lung injury indicator:Serum soluble receptor for advanced glycation end products (sRAGE,pg/mL)

    Peripheral blood samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to measure serum sRAGE levels (pg/mL), which serves as a biomarker of pulmonary epithelial injury.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  13. Lung injury indicator:Electrical impedance tomography (EIT) parameters of lung ventilation

    Lung ventilation distribution will be monitored by EIT at baseline (pre-treatment), Day 3, and Day 7 of treatment to assess lung injury-related indicators including lung collapse, overdistension, and ventilation inhomogeneity.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  14. Ventilator parameter:Pressure support (PS, cmH₂O)

    The pressure support level provided by the ventilator (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  15. Ventilator parameter:Positive end-expiratory pressure (PEEP, cmH₂O)

    The positive airway pressure maintained at the end of expiration (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  16. Ventilator parameter:Fraction of inspired oxygen (FiO₂, %)

    The fraction of inspired oxygen set on the ventilator (in %) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  17. Pulmonary vascular permeability indicator: Lung ultrasound B-line score

    The number and distribution of B-lines are assessed and scored by lung ultrasound at baseline (pre-treatment), Day 3, and Day 7 of treatment. A higher number and more diffuse distribution of B-lines indicate more severe pulmonary edema. This score is used to evaluate pulmonary vascular permeability and the severity of pulmonary edema.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  18. Inflammatory indicator:Tumor necrosis factor-α (TNF-α,pg/mL)

    Serum TNF-α levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  19. Inflammatory indicator:C-reactive protein (CRP,mg/L)

    Serum CRP levels (mg/L) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  20. Inflammatory indicator:Procalcitonin (PCT,ng/mL)

    Serum PCT levels (ng/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.

    Time frame: Before treatment,on day 3 of treatment,on day 7 of treatment

  21. Microecology:Gut Microbiota Alpha Diversity (Shannon Index)

    Fecal samples (10g) will be collected at baseline, day 3, and day 7 of treatment. 16S rRNA high-throughput sequencing will be performed to analyze gut microbiota alpha diversity (Shannon index, unitless) to evaluate changes in intestinal microecological homeostasis.

    Time frame: Baseline, Day 3, Day 7 of treatment

  22. Metabolomics analysis:Serum Target Metabolite Concentration

    Peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Untargeted metabolomics will be performed to detect the concentration of target serum metabolites, with the unit of μmol/L, to evaluate changes in the body's metabolic status.

    Time frame: Baseline, Day 3, Day 7 of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.

Of 39 phase 3 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 14, 2026
StartEst.
Aug 20, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07528196
Collaborators
Beijing Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou Medical University, Jiangsu Province Hospital of Traditional Chinese Medicine, Subei People's Hospital of Jiangsu Province, Wuhan Hospital of Traditional Chinese Medicine, Shenzhen Hospital of Traditional Chinese Medicine
Responsible party
Ling Liu (Professor, Southeast University, China) — Principal investigator
First posted
Apr 14, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Airan Liu, PhD
Contact
airanliu@126.com
+8615295557466

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion